condition found
Features: Anti-oxidant, anti-tumor |
Thymoquinone is a bioactive compound found in the seeds of Nigella sativa, commonly known as black seed or black cumin. Pathways: -Cell cycle arrest, apoptosis induction, ROS generation in cancer cells -inhibit the activation of NF-κB, Suppress the PI3K/Akt signaling cascade -Inhibit angiogenic factors such as VEGF, MMPs -Inhibit HDACs, UHRF1, and DNMTs -Note half-life 3-6hrs. BioAv low oral bioavailability due to its lipophilic nature. Note refridgeration of Black seed oil improves the stability of TQ. DIY: ~1 part lecithin : 2–3 parts black seed oil : 4–5 parts warm water. (chat ai) Pathways: - usually induce ROS production in Cancer cells, and lowers ROS in normal cells - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx, - May Low AntiOxidant defense in Cancer Cells: NRF2↓(usually contrary), GSH↓ HO1↓(contrary), GPx↓ - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, FAK↓, NF-κB↓, CXCR4↓, TGF-β↓, ERK↓ - reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, TET↑ - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, - inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PDKs↓, GRP78↑, GlucoseCon↓ - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, EGFR↓, Integrins↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK, - Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells |
Source: |
Type: |
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
3397- | TQ,  |   | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
- | Review, | CRC, | NA |
3424- | TQ,  |   | Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex |
- | Review, | Var, | NA |
3422- | TQ,  |   | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
- | Review, | Var, | NA |
3421- | TQ,  |   | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
- | Analysis, | Nor, | NA | - | in-vivo, | Nor, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HaCaT |
1936- | TQ,  |   | Thymoquinone induces apoptosis and increase ROS in ovarian cancer cell line |
- | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Nor, | WRL68 |
2096- | TQ,  |   | Effect of total hydroalcholic extract of Nigella sativa and its n-hexane and ethyl acetate fractions on ACHN and GP-293 cell lines |
- | in-vitro, | Nor, | GP-293 | - | in-vitro, | Kidney, | ACHN |
2093- | TQ,  |   | Regulation of NF-κB Expression by Thymoquinone; A Role in Regulating Pro-Inflammatory Cytokines and Programmed Cell Death in Hepatic Cancer Cells |
- | in-vitro, | Liver, | HepG2 | - | in-vitro, | Nor, | NA |
2084- | TQ,  |   | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation |
- | Review, | Var, | NA |
2097- | TQ,  |   | Crude extract of Nigella sativa inhibits proliferation and induces apoptosis in human cervical carcinoma HeLa cells |
- | in-vitro, | Cerv, | HeLa |
1935- | TQ,  |   | Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis |
- | Review, | OS, | NA |
2124- | TQ,  |   | Thymoquinone: an emerging natural drug with a wide range of medical applications |
- | Review, | Var, | NA |
2110- | TQ,  |   | Nigella sativa seed oil suppresses cell proliferation and induces ROS dependent mitochondrial apoptosis through p53 pathway in hepatocellular carcinoma cells |
- | in-vitro, | HCC, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
2106- | TQ,  |   | Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy |
- | Review, | Var, | NA |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:162 Target#:1110 State#:% Dir#:%
wNotes=on sortOrder:rid,rpid